bepirovirsen   Click here for help

GtoPdb Ligand ID: 14707

Synonyms: GSK-3228836 | GSK-3228836B | GSK-3389404 | GSK3389404 | Hibsago® | IONIS HBVRX | ISIS-505358 | ISIS-GSK3RX
Approved drug
bepirovirsen is an approved drug
Compound class: Nucleic acid
Comment: Bepirovirsen (GSK3389404) is an antisense oligonucleotide (ASO) therapy that is proposed as a functional cure for chronic hepatitis B, by binding to hepatitis B virus RNA and preventing viral protein translation and replication. It may also mediate HBV mRNA degradation, potentially via the innate immune response initiated by its CpG motif [2]. The molecule is N-acetylgalactosamine (GalNAc)-conjugated to enhance hepatocyte delivery.

Full necletide sequence is all-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine
No information available.
Summary of Clinical Use Click here for help
Bepirovirsen was progressed as a clinical candidate anti-hepatitis B therapeutic [1]. First approval for clinical use was granted by Japan's PMDA in August 2026. US FDA approval followed in October 2026.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04449029 A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) Phase 2 Interventional GlaxoSmithKline 4
NCT05630820 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Phase 3 Interventional GlaxoSmithKline 1
NCT05630807 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) Phase 3 Interventional GlaxoSmithKline 1
NCT03020745 A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects Phase 2 Interventional GlaxoSmithKline 3